News Briefs: eMed refiles IPO, acquires Trilix
eMed refiles IPO, acquires TrilixeMed Technologies is moving ahead with plans to expand its portfolio of Internet-based products and services, fueled in large part by the prospect of a pending $46 million initial public offering. The Lexington,
eMed refiles IPO, acquires Trilix
eMed Technologies is moving ahead with plans to expand its portfolio of Internet-based products and services, fueled in large part by the prospect of a pending $46 million initial public offering. The Lexington, MA-based company originally filed for an IPO last August (PNN 9/99) but postponed the offering one month later, citing market volatility with regard to health-related IPOs (PNN 11/99). Apparently sensing a more positive climate on Wall Street these days, eMed refiled its IPO with the Securities and Exchange Commission Feb. 25.
In related news, eMed acquired Trilix Information Systems, a software company founded by several former Cemax-Icon engineers. Trilix, headquartered in Pleasanton, CA, provides integration technology that allows the exchange of information among different healthcare imaging and information systems, both within a hospitals network and via the Internet. The addition of Trilixs technology to eMeds image-management products and services should help facilitate an organizations move toward electronic medical records, providing clinicians with connectivity to diagnostic images, as well as to laboratory, pathology, and other diagnostic reports.
eMed also plans to make Trilixs interface technologies available to other vendors on an OEM basis. Trilix already has OEM relationships with Kodak and Canon, according to company sources. eMed acquired Trilix in a straight stock deal.
© 2000 Miller Freeman, Inc., a United News & Media company.
- Search again
- Homepage
Considering Breast- and Lesion-Level Assessments with Mammography AI: What New Research Reveals
June 27th 2025While there was a decline of AUC for mammography AI software from breast-level assessments to lesion-level evaluation, the authors of a new study, involving 1,200 women, found that AI offered over a seven percent higher AUC for lesion-level interpretation in comparison to unassisted expert readers.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
